Do lipid lowering drugs reduce the risk of coronary heart disease?

Critical Reviews in Clinical Laboratory Sciences

Volumn 35, Issue 6, 1998, Pages 603-621

  Pritzker, L B ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Cholesterol; Cholestyramine; Clinical trials; Coronary angiography; Coronary heart disease; Fibrates; Myocardial infarction; Niacin; Probucol; Statins; Triglyceride

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STATIN; TRIACYLGLYCEROL;

ANGIOGRAPHY; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CORONARY RISK; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

ANGIOGRAPHY; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; CLINICAL TRIALS; CLOFIBRATE; CORONARY ARTERIOSCLEROSIS; CORONARY DISEASE; EUROPE; HUMANS; LIPOPROTEINS, LDL; PRAVASTATIN; SURVIVAL RATE;

EID: 0032424372     PISSN: 10408363     EISSN: None     Source Type: Journal    
DOI: 10.1080/10408369891234291     Document Type: Review

References (41)

1. Feyter PJD, Vos J Deckers JW. Progression and regression of the atherosclerotic plaque. Eur Heart J 1995; 16(Suppl. I): 26-30.
2. Dawber TR, Moore FE Mann GV. Coronary heart disease in the Framingham Study. Am J Public Health 1957; 47(Suppl.): 4-23.
3. McGill HC. Overview. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and coronary artery disease. Pp. 25-41 Philadelphia: Lippincott-Raven Publishers, 1996: vol 1.
4. Superko HR, Krauss RM. Coronary artery disease regression: convincing evidence for the benefit of aggressive lipoprotein management. Circulation 1994; 90: 1056-1069.
5. Brown BG, Zhao X-Q, Sacco DE, et al. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87: 1781-1791.
6. Gotto AM. Lipid lowering, regression and coronary events. Circulation 1995; 92: 646-656.
7. Tyroler HA. Review of lipid-lowering clinical trials in relation to observational epidemiologic studies. Circulation 1987; 76: 515-522.
8. Little JA. Coronary prevention and regression studies updated. Can J Cardiol 1988; 4(Suppl. A): 11A-15A.
9. Marchioli R, Marfisi RM, Carinci F, et al. Meta-analysis, clinical trials and transferability of research results into practice. Ann Intern Med 1996; 156: 1158-1172.
10. Brown BG, Zhao X-Q, Sacco DE, et al. Atherosclerosis regression, plaque disruption and cardiovascular events: a rationale for lipid lowering in coronary artery disease. Annu Rev Med 1993; 44: 365-76.
11. Grundy SM. Cholesterol and coronary heart disease. Arch Intern Med 1997; 157: 1177-1184.
12. Mack WJ, Hodis HN. Efficacy of interventions designed to inhibit the progression of coronary atherosclerosis. Diab Res Clin Pract 1996; 30: S37-S53.
13. Blankenhorn DH, Hodis HN. Arterial imaging and atherosclerosis reversal. Arterioscler Thromb 1994; 14: 177-92.
14. Fuster V. Mechanisms of arterial thrombosis: foundation for therapy. Am Heart J 1998; 135: S361-366.
15. Farmer JA, Gotto AM. Management. In: Fuster V, Ross R Topol EJ, eds. Atherosclerosis and coronary artery disease. Pp. 171-190 Philadelphia: Lippincott-Raven Publishers, 1996: vol 1.
16. Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous by-pass grafts. JAMA 1987; 257: 3233-3240.
17. Azen SP, Mack WJ, Cashin-Hemphill L, et al. Progression of coronary artery disease predicts clinical coronary events - long-term follow-up from the cholesterol lowering atherosclerosis study. Circulation 1996; 93: 34-41.
18. Watts GF, Lewis B, Brunt JNH, et al. Effects on coronary disease of lipid-lowering diet or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992; 339: 563-569.
19. Haskell WL, Alderman EL, Fair JM, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. Circulation 1994; 89: 975-990.
20. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289-1298.
21. Zhao X-Q, Brown BG, Hillger L, et al. Effects of intensive lipid-lowering therapy on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B. Circulation 1993; 88: 2744-2753.
22. Pitt B, Mancini GBJ, Ellis SG, et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol 1995; 26: 1133-1139.
23. Herd JA, Ballantyne CM, Farmer JA, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (lipoprotein and coronary atherosclerosis study [LCAS]). Am J Cardiol 1997; 80: 278-286.
24. Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. Circulation 1994; 89: 959-968.
25. Furburg CD, Adams HP, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994; 90: 1679-1687.
26. Investigators MAAS. Effect of simvastatin on coronary atheroma: the multicentre anti-atheroma study (MAAS). Lancet 1994; 344: 633-38.
27. Oliver MF, Heady JA, Morris JN, et al. A Cooperative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978; 40: 1069-1118.
28. Program Lipid Research Clinics. The Lipid Research Clinics Coronary Primary Prevention Trial Results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-364.
29. Frick MH, Elo OE, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987; 317: 1237-45.
30. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
31. Group West of Scotland Coronary Prevention Study. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular trials. Lancet 1996; 348: 1339-42.
32. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998; 279: 1615-1622.
33. Group Scandinavian Simvastatim Survival Study. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatim survival study (4S). Lancet 1994; 344: 1383-89.
34. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
35. Superko HR. Beyond LDL cholesterol reduction. Circulation 1996; 94: 2351-2354.
36. Leung WH, Lau CP Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. Lancet 1993; 341: 1496-1500.
37. O'Driscoll G, Green D Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126-1131.
38. Aviram M. Interaction of low density lipoprotein with macrophages in atheroscleosis and the antiatherogenicity of antioxidants. Eur J Clin Chem Clin Biochem 1996; 34: 599-608.
39. Corsini A, Pazzucconi F, Pfister P, et al. Inhibitor of proliferation of arterial smooth muscle cells by fluvastatin [letter]. Lancet 1996; 348: 1584.
40. Benderly M, Graff E, Reicher-Reiss H, et al. Fibrinogen is a predictor of mortality in coronary heart disease patients. Arteroscler Thromb Vasc Biol 1996; 16: 351-356.
41. Broijersen A, Eriksson M, Wiman B, et al. Gemfibrozil treatment of combined hyperlipoproteinemia: no improvement despite marked reduction of plasma triglyceride levels. Arterioscler Thromb Vasc Biol 1996; 16: 511-516.